Gene therapy improves motor and mental function of aromatic l-amino acid decarboxylase deficiency
Open accessThe DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Abstract
In patients with aromatic l-amino acid decarboxylase (AADC) deficiency, a decrease in catecholamines and serotonin levels in the brain leads to developmental delay and movement disorders. The beneficial effects of gene therapy in patients from 1 to 8 years of age with homogeneous severity of disease have been reported from Taiwan. We conducted an open-label phase 1/2 study of population including adolescent patients with different degrees of severity. Six patients were enrolled: four males (ages 4, 10, 15 and 19 years) and one female (age 12 years) with a severe phenotype who were not capable of voluntary movement or speech, and one female (age 5 years) with a moderate phenotype who could walk with support. The patients received a total of 2 × 1011 vector genomes of adeno-associated virus vector harbouring DDC via bilateral intraputaminal infusions. At up to 2 years after gene therapy, the motor function was remarkably improved in all patients. Three patients with the severe phenotype were able to stand with support, and one patient could walk with a walker, while the patient with the moderate phenotype could run and ride a bicycle. This moderate-phenotype patient also showed improvement in her mental function, being able to converse fluently and perform simple arithmetic. Dystonia disappeared and oculogyric crisis was markedly decreased in all patients. The patients exhibited transient choreic dyskinesia for a couple of months, but no adverse events caused by vector were observed. PET with 6-[18F]fluoro-l-m-tyrosine, a specific tracer for AADC, showed a persistently increased uptake in the broad areas of the putamen. In our study, older patients (>8 years of age) also showed improvement, although treatment was more effective in younger patients. The genetic background of our patients was heterogeneous, and some patients suspected of having remnant enzyme activity showed better improvement than the Taiwanese patients. In addition to the alleviation of motor symptoms, the cognitive and verbal functions were improved in a patient with the moderate phenotype. The restoration of dopamine synthesis in the putamen via gene transfer provides transformative medical benefit across all patient ages, genotypes, and disease severities included in this study, with the most pronounced improvements noted in moderate patients.10.1093/brain/awy331_video1awy331media15991361892001.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“two weaned off mechanical ventilation”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [61]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“four regained the ability to eat by mouth”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [61]
The cited source says what the claim attributes to it.
In the citing paper
“Within 2 months, all had improvement in their voluntary movements”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [61]
In the citing paper
“all showed improvements in dystonic episodes, irritability, and autonomic dysfunction.61”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functional architecture of basal ganglia circuits: neural substrates of parallel processing
Alexander, G. E., & Crutcher, M. D. (1990) · Trends in Neurosciences · doi:10.1016/0166-2236(90)90107-l · Cited by 4,131
Basal ganglia and cerebellar loops: motor and cognitive circuits
Middleton, F. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00040-5 · Cited by 1,940
Modulation of Striatal Projection Systems by Dopamine
Gerfen, C. R., & Surmeier, D. J. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113641 · Cited by 1,718
Role of the Basal Ganglia in the Control of Purposive Saccadic Eye Movements
Hikosaka, O., Takikawa, Y., & Kawagoe, R. (2000) · Physiological Reviews · doi:10.1152/physrev.2000.80.3.953 · Cited by 1,302 · cited 1×
“Cortico-basal ganglia loops, such as motor, prefrontal, limbic and oculomotor loops, have been proposed as functions of the basal ganglia (Alexander et al., 1990; Hikosaka et al., 2000; Middleton and Strick, 2000).”
BackgroundAdaptive segmentation of MRI data
Wells, W. M., Grimson, W. E. L., Kikinis, R., & Jolesz, F. A. (1996) · IEEE Transactions on Medical Imaging · doi:10.1109/42.511747 · Cited by 1,277
Dichotomous dopaminergic control of striatal synaptic plasticity
Shen, W., Flajolet, M., Greengard, P., & Surmeier, D. J. (2008) · Science · doi:10.1126/science.1160575 · Cited by 1,190 · cited 1×
“Dopamine is reported to play a role in synaptic plasticity, modulating glutamatergic neurons in order to enhance the synaptic connection to create a neuronal network (Calabresi et al., 2007; Shen et al., 2008).”
BackgroundSynaptic organisation of the basal ganglia
BOLAM, J. P., HANLEY, J. J., BOOTH, P. A. C., & BEVAN, M. D. (2000) · Journal of Anatomy · doi:10.1046/j.1469-7580.2000.19640527.x · Cited by 948 · cited 1×
“The main pathway for dopaminergic control of the motor function system is from the substantia nigra to the striatum (Bolam et al., 2000; Gerfen et al., 2011).”
BackgroundDopamine-mediated regulation of corticostriatal synaptic plasticity
Calabresi, P., Picconi, B., Tozzi, A., & Di Filippo, M. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.001 · Cited by 865 · cited 1×
“Dopamine is reported to play a role in synaptic plasticity, modulating glutamatergic neurons in order to enhance the synaptic connection to create a neuronal network (Calabresi et al., 2007; Shen et al., 2008).”
BackgroundYung, K. K. L., Bolam, J. P., Smith, A. D., Hersch, S. M., Ciliax, B. J., & Levey, A. I. (1995) · Neuroscience · doi:10.1016/0306-4522(94)00536-e · Cited by 542 · cited 1×
“Furthermore, as dopamine receptors are reported to exist all over the dendrites and not in the postsynaptic membrane alone, these receptors might be stimulated, thus allowing a sufficient dopamine effect to be obtained (Yung et al., 1995; Uchigashima et al., 2016).”
BackgroundHereditary progressive dystonia with marked diurnal fluctuation
Segawa, M., & Nomura, Y. (1991) · Key Topics in Brain Research · doi:10.1007/978-3-7091-9146-0_17 · Cited by 473
Research works printed but not linked: 1
- Vitek, 1999, Neuronal activity in the basal ganglia in patients with generalized dystonia and hemiballismus, Ann Neurol, 46, 22, 10.1002/1531-8249(199907)46:1<22::AID-ANA6>3.0.CO;2-Z · doi:10.1002/1531-8249(199907)46:1<22::aid-ana6>3.0.co;2-z
Cited by
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
“Within 2 months, all had improvement in their voluntary movements, two weaned off mechanical ventilation, four regained the ability to eat by mouth, and all showed improvements in dystonic episodes, irritability, and autonomic dysfunction.(61)”
BackgroundResultPearson, T. S., Gupta, N., San Sebastian, W., Imamura-Ching, J., Viehoever, A., Grijalvo-Perez, A., Fay, A. J., Seth, N., Lundy, S. M., Seo, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24524-8 · Cited by 186
Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency
Tai, C.-H., Lee, N.-C., Chien, Y.-H., Byrne, B. J., Muramatsu, S.-I., Tseng, S.-H., & Hwu, W.-L. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2021.11.005 · Cited by 162
“The increase in PDMS-2 total scores after eladocagene exuparvovec treatment had a negative correlation with age (Table S1), indicating that younger patients exhibited faster and greater improvements in PDMS-2 scores after gene therapy, a finding similar to previous publications.(16,18) This is likely related to a grea…”
Self-citationProkineticin-2 prevents neuronal cell deaths in a model of traumatic brain injury
Bao, Z., Liu, Y., Chen, B., Miao, Z., Tu, Y., Li, C., Chao, H., Ye, Y., Xu, X., Sun, G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24469-y · Cited by 152
AAV vectors applied to the treatment of CNS disorders: Clinical status and challenges
Kang, L., Jin, S., Wang, J., Lv, Z., Xin, C., Tan, C., Zhao, M., Wang, L., & Liu, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.067 · Cited by 131
Current clinical applications of AAV-mediated gene therapy
Byrne, B. J., Flanigan, K. M., Matesanz, S. E., Finkel, R. S., Waldrop, M. A., D'Ambrosio, E. S., Johnson, N. E., Smith, B. K., Bönnemann, C. G., Carrig, S., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.045 · Cited by 162
Qi, B., He, L., Zhao, Y., Zhang, L., He, Y., Li, J., Li, C., Zhang, B., Huang, Q., Xing, J., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05103-w · Cited by 123
Treatable inherited metabolic disorders causing intellectual disability: 2021 review and digital app
van Konijnenburg, E. M. M. H., Wortmann, S. B., Koelewijn, M. J., Tseng, L. A., Houben, R. F. A., Stöckler‐Ipsiroglu, S., Ferreira, C. R., & van Karnebeek, C. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01727-2 · Cited by 126
Aromatic amino acid decarboxylase deficiency: Molecular and metabolic basis and therapeutic outlook
Himmelreich, N., Montioli, R., Bertoldi, M., Carducci, C., Leuzzi, V., Gemperle-Britschgi, C., Berner, T., Hyland, Κ., Thöny, B., Hoffmann, G. F., et al. (2019) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2019.03.009 · Cited by 104
Pearson, T. S., Gilbert, L. A., Opladen, T., García‐Cazorla, À., Mastrangelo, M., Leuzzi, V., Tay, S. K. H., Sykut‐Cegielska, J., Pons, R. M., Mercimek‐Andrews, S., et al. (2020) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12247 · Cited by 101
Self-citationDaci, R., & Flotte, T. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021050 · Cited by 81
“The authors chose to inject the putamen because the putamen receives dopaminergic projections from the substantia nigra, and dopamine depletion in the putamen causes the loss of voluntary motor movement [20].”
BackgroundInfluentialBlood–brain barrier opening with focused ultrasound in experimental models of Parkinson's disease
Karakatsani, M. E., Blesa, J., & Konofagou, E. E. (2019) · Movement Disorders · doi:10.1002/mds.27804 · Cited by 60
“For example, recent clinical trials involved invasive putaminal injections.(53,70) AAV-AADC (Aromatic L-amino acid decarboxylase) delivery proved to improve motor function,(70) whereas AAV-GDNF did not meet its primary endpoint and did not provide clinical benefits.”
MethodTranslational Feasibility of Lumbar Puncture for Intrathecal AAV Administration
Hinderer, C. J., Katz, N., Dyer, C., Goode, T. L., Johansson, J., Bell, P. L., Richman, L. K., Buza, E. L., & Wilson, J. M. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.04.012 · Cited by 57
“Although this approach is promising for some diseases, intraparenchymal injection is an invasive procedure that results in limited distribution of the vector beyond the injection site, thus making it unsuitable for many applications.(3,4) Expanding the potential of AAV gene therapy to new targets will require the iden…”
BackgroundEnzymatic synthesis of fluorinated compounds
Cheng, X., & Ma, L. (2021) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-021-11608-0 · Cited by 51
Gene therapy in the putamen for curing AADC deficiency and Parkinson's disease
Hwu, W., Kiening, K. L., Anselm, I. A., Compton, D. M., Nakajima, T., Opladen, T., Pearl, P. L., Roubertie, A., Roujeau, T., & Muramatsu, S. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114712 · Cited by 49
“The efficacy and safety of AAV2 gene therapy via intraputaminal bilateral infusions in children with AADC deficiency ( n = 20) have been investigated in 3 clinical trials conducted by different investigators (Hwu et al , 2012; Chien et al , 2017; Kojima et al , 2019).”
InfluentialSelf-citationBrennenstuhl, H., Kohlmüller, D., Gramer, G., Garbade, S. F., Syrbe, S., Feyh, P., Kölker, S., Okun, J. G., Hoffmann, G. F., & Opladen, T. (2019) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12208 · Cited by 33
“A comparable study from Japan confirmed these results and revealed a negative correlation between patient age and treatment outcome.(6) Furthermore, corticospinal tract analysis showed improvement of fractional anisotropy, which is connected to increased diffusion of white matter and increased myelination.”
BackgroundResultTreatable Hyperkinetic Movement Disorders Not to Be Missed
Méneret, A., Garcin, B., Frismand, S., Lannuzel, A., Mariani, L., & Roze, E. F. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.659805 · Cited by 39
“Of note, another neurotransmitter disease, aromatic L-amino acid decarboxylase (AADC) deficiency, which causes developmental delay and movement disorders, may be effectively treated by gene therapy (189).”
BackgroundClinical Features in Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency: A Systematic Review
Rizzi, S., Spagnoli, C., Frattini, D., Pisani, F., & Fusco, C. (2022) · Behavioural Neurology · doi:10.1155/2022/2210555 · Cited by 38
“In fact, patients with moderate phenotypes show better improvement than severely affected patients [7].”
BackgroundHarkins, A. L., Ambegaokar, P. P., & Keeler, A. M. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00435 · Cited by 39
“Across studies, patients reported intracranial hemorrhages and headaches due to the surgical procedure [66,71,74,75,83].”
Rossignoli, G., Krämer, K., Lugarà, E., Alrashidi, H., Pope, S. A. S., Barrigon, C. D. L. F., Barwick, K. E., Bisello, G., Ng, J., Counsell, J. R., et al. (2021) · Brain · doi:10.1093/brain/awab123 · Cited by 31
Gene Therapy in Movement Disorders: A Systematic Review of Ongoing and Completed Clinical Trials
Merola, A., Kobayashi, N., Romagnolo, A., Wright, B. A., Artusi, C. A., Imbalzano, G., Litvan, I., Laar, A. D. V., & Bankiewicz, K. S. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.648532 · Cited by 33
“(33) 2 × 10(11) vg−200 μL 24 Safety and tolerability Motor and cognitive functions”
BackgroundResultInfluentialRoubertie, A., Opladen, T., Brennenstuhl, H., Hübschmann, O. K., Flint, L. Y., Willemsen, M. A. A. P., Leuzzi, V., Cazorla, À. G., Kurian, M. A., François-Heude, M. C., et al. (2023) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12649 · Cited by 31
“12,17,18 In July 2022, PTC Therapeutics, Inc. received the marketing authorization of Eladocagene exuparvovec (Upstaza ® ) for the intraputaminal administration from the European Medicines Agency (EMA) and in February 2023 from the British Medicines and Healthcare products Regulatory Agency (MHRA)…”
BackgroundResultA Proposed Diagnostic Algorithm for Inborn Errors of Metabolism Presenting With Movements Disorders
Ortigoza‐Escobar, J. D. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.582160 · Cited by 31
Burlina, A., Giuliani, A., Polo, G., Gueraldi, D., Gragnaniello, V., Cazzorla, C., Opladen, T., Hoffmann, G. F., Blau, N., & Burlina, A. P. (2021) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2021.03.009 · Cited by 29
In vivo applications and toxicities of AAV-based gene therapies in rare diseases
Zhao, Q., Peng, H., Ma, Y., Yuan, H., & Jiang, H. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-03893-z · Cited by 33
Wen, Y., Wang, J., Zhang, Q., Chen, Y., & Bao, X. (2020) · Journal of Human Genetics · doi:10.1038/s10038-020-0770-6 · Cited by 28
Bosma, P. J., Wits, M., & Elferink, R. P. J. O. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010273 · Cited by 28
“For instance this approach as a treatment for Choroidenemia [31], aromatic L-amino acid decarboxylase deficiency [32], Pompe’s Disease [33,34], Duchenne Muscular Dystrophy (ongoing: NCT03375164), Becker’s Muscular Dystrophy [35], Limb-Girdle Muscular Dystrophy [36], X-linked myotubular myopathy (ongoing: NCT03199469),…”
MethodGene Therapy for Dopamine Dyshomeostasis: From Parkinson's to Primary Neurotransmitter Diseases
Ng, J., Barral, S., Waddington, S. N., & Kurian, M. A. (2023) · Movement Disorders · doi:10.1002/mds.29416 · Cited by 29
Hemophilia gene therapy—New country initiatives
Reiss, U. M., Zhang, L., & Ohmori, T. (2020) · Haemophilia · doi:10.1111/hae.14080 · Cited by 54
New variants of AADC deficiency expand the knowledge of enzymatic phenotypes
Montioli, R., Bisello, G., Dindo, M., Rossignoli, G., Voltattorni, C. B., & Bertoldi, M. (2020) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2020.108263 · Cited by 26
Neurosurgical gene therapy for central nervous system diseases
Patel, R. V., Nanda, P., & Richardson, R. M. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00434 · Cited by 23
Himmelreich, N., Montioli, R., Garbade, S. F., Kopesky, J. W., Elsea, S. H., Carducci, C., Voltattorni, C. B., & Blau, N. (2022) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2022.11.003 · Cited by 26
Kuwayama, R., Suzuki, K., Nakamura, J., Aizawa, E., Yoshioka, Y., Ikawa, M., Nabatame, S., Inoue, K., Shimmyo, Y., Ozono, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30847-x · Cited by 27
Revisiting gene delivery to the brain: silencing and editing
Conniot, J., Talebian, S., Simões, S. M. N., Ferreira, L., & Conde, J. (2021) · Biomaterials Science · doi:10.1039/d0bm01278e · Cited by 25
Nucleic Acid–Based Therapeutics in Orphan Neurological Disorders: Recent Developments
Khorkova, O., Hsiao, J. H., & Wahlestedt, C. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.643681 · Cited by 23
“Treatment was more effective in younger patients (Kojima et al., 2019).”
BackgroundSpaull, R., Soo, A. K. S., Hogarth, P., Hayflick, S. J., & Kurian, M. A. (2021) · Tremor and Other Hyperkinetic Movements · doi:10.5334/tohm.661 · Cited by 24
Onuki, Y., Ono, S., Nakajima, T., Kojima, K., Taga, N., Ikeda, T., Kuwajima, M., Kurokawa, Y., Kato, M., Kawai, K., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab078 · Cited by 22
“Recently, as a disease-modifying therapy for AADC deficiency, adeno-associated virus (AAV) vector-mediated delivery of DDC into the putamen was shown to provide transformative medical benefits across various patient ages, genotypes and disease severities.(1,2) We had earlier demonstrated marked improvement of both cog…”
BackgroundMethodInfluentialSelf-citationRajendran, K., Chellappan, D. R., Sankaranarayanan, S., Ramakrishnan, V., & Krishnan, U. M. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104890 · Cited by 17
Macdonald, J., Marx, J., & Büning, H. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.169 · Cited by 18
Adeno-associated virus vector-based gene therapies for pediatric diseases
Muramatsu, K., & Muramatsu, S. (2022) · Pediatrics & Neonatology · doi:10.1016/j.pedneo.2022.09.004 · Cited by 16
“Gene therapy for aromatic L-amino acid decarboxylase (AADC) deficiency is a representative example of successful gene therapy.(10,11) In this therapy, AAV vectors expressing the AADC gene were injected into the putamen by stereotaxic brain surgery.”
MethodSelf-citationIntraputaminal Gene Delivery in Two Patients with Aromatic L‐Amino Acid Decarboxylase Deficiency
François‐Heude, M., Poulen, G., Roze, E. F., Nguyen-Morel, M.-A., Gras, D., Roch-Torreilles, I., Quintard, A., Baroux, G., Meyer, P., Coubes, P. A., et al. (2023) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13685 · Cited by 17
“Indeed, Kojima et al(9) reported four patients >10 years old with improvement of cognitive and motor functions (head control and sitting with support: all patients before 8 months after GD; stand with support: 3 of 4 patients before 18 months after GD; aided walk: 1 patient; all patients could grip at the last follow-…”
BackgroundDai, W., Lu, D., Gu, X., Yu, Y., & Disease, T. M. C. L. O. A. R. (2020) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.1143 · Cited by 16
“Gene therapy which has become an emerging approach for treating disease, was performed in a small group of AADCD patient with modest but promising results (Zwagerman and Richardson, 2012; Kojima et al., 2019).”
BackgroundHanbury, A., Smith, A. B., & Buesch, K. (2021) · Patient Related Outcome Measures · doi:10.2147/prom.s278258 · Cited by 15
“This provides reassurance that the health states capture what it is like to live with AADC deficiency, despite the idiopathic nature of it, and supports the assertion of Kojima et al.(2) that global improvements can be seen in AADC deficiency.”
BackgroundResultGene therapy for neurotransmitter‐related disorders
Chu, W. S., Ng, J., Waddington, S. N., & Kurian, M. A. (2024) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12697 · Cited by 16
“From a clinical perspective, different inclusion ages (Upstaza ™ 18 months and over, Kojima et al. 73,75 and Pearson et al. 77,79 4 years and over, VGN-R09b 80 2 – 8 years old), variable baseline disease severity, and relatively small patient groups may make direct comparison difficult, as well as…”
BackgroundMethodHosaka, T., Tsuji, H., & Kwak, S. (2023) · Cells · doi:10.3390/cells12101443 · Cited by 16
Muñoz-Melero, M., & Biswas, M. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.227 · Cited by 14
Williams, K., Skrobanski, H., Werner, C., O’Neill, S., Buesch, K., & Acaster, S. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1932449 · Cited by 12
Bisello, G., & Bertoldi, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911238 · Cited by 14
Aromatic L-amino acid decarboxylase deficiency: a systematic review
Bergkvist, M., Stephens, C., Schilling, T., Wang, A., Yu, X., Goodwin, E., Golden, L., Kristensen, A., & Klein, M. B. (2022) · Future Neurology · doi:10.2217/fnl-2022-0012 · Cited by 13
Kumagai, S., Nakajima, T., & Muramatsu, S. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2386339 · Cited by 11
“Gene therapy for children with AADC deficiency has shown that AAV vector-mediated gene transfer of the AADC ( DDC ) into the putamen effectively restores motor function [59–61].”
Self-citationBrennenstuhl, H., Garbade, S. F., Okun, J. G., Feyh, P., Hoffmann, G. F., Langhans, C., & Opladen, T. (2020) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2020.07.001 · Cited by 11
In vitro functional analysis of four variants of human asparagine synthetase
Matsumoto, H., Kawashima, N., Yamamoto, T., Nakama, M., Otsuka, H., Ago, Y., Sasai, H., Kubota, K., Ozeki, M., Kawamoto, N., et al. (2021) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12408 · Cited by 11
“Studies have examined the practical application of gene therapy for unsettled inborn errors of metabolism.(20,21) For example, gene therapy using adeno-associated viral vectors for aromatic L-amino acid decarboxylase deficiency that causes severe damage of the central nervous system from a very early stage of life sim…”
BackgroundClinical and biochemical footprints of inherited metabolic diseases. XV. Epilepsies
Latzer, I. T., Blau, N., Ferreira, C. R., & Pearl, P. L. (2023) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2023.107690 · Cited by 14
Phenotypes and Genotypes of Inherited Disorders of Biogenic Amine Neurotransmitter Metabolism
Mastrangelo, M., Tolve, M., Artiola, C., Bove, R., Carducci, C., Carducci, C., Angeloni, A., Pisani, F., & Leuzzi, V. (2023) · Genes · doi:10.3390/genes14020263 · Cited by 10
Skrobanski, H., Williams, K., Werner, C., O’Neill, S., Buesch, K., & Acaster, S. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1955668 · Cited by 13
Dual-vector rAAVrh8 gene therapy for GM2 gangliosidosis: a phase 1/2 trial
Eichler, F., Cataltepe, O. I., Daci, R., Puri, A. S., Taghian, T., Jiang, X., Shazeeb, M. S., Kühn, A. L., Hader, A., Celik, H., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03822-4 · Cited by 13
Blood, urine and cerebrospinal fluid analysis in TH and AADC deficiency and the effect of treatment
Wassenberg, T., Geurtz, B., Monnens, L. A. H., Wevers, R. A., Willemsen, M. A. A. P., & Verbeek, M. M. (2021) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2021.100762 · Cited by 15
“Treatment of AADC deficiency is complex and often little successful [4], although promising results of gene therapy have been obtained recently [6,7].”
BackgroundMiyamoto, M., Miyamoto, T., Saitou, J., & Satō, T. (2019) · Sleep Medicine · doi:10.1016/j.sleep.2019.09.013 · Cited by 11
Treatment of neurometabolic epilepsies: Overview and recent advances
Latzer, I. T., & Pearl, P. L. (2023) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2023.109181 · Cited by 9
Hwu, W., Lee, H.-M., Peipert, J. D., Zhang, R., Werner, C., Sierra, J. R., O’Connell, T., Woolley, J. J., Crowell, M., Wang, A., et al. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-03584-9 · Cited by 8
“In the elado-cagene exuparvovec trials, the Reflexes subtest was not assessed (8 items,16 total possible points), resulting in a Total PDMS-2 score range of 0-482 [7, 12–14].”
Chen, P.-W., Hwu, W., Lee, N., & Chien, Y. (2023) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2023.107687 · Cited by 9
Gowda, V. K., Vegda, H., Nagarajan, B., & Shivappa, S. K. (2020) · Journal of Pediatric Genetics · doi:10.1055/s-0040-1714690 · Cited by 10
Hasegawa, Y., Nishi, E., Mishima, Y., Sakaguchi, T., Sekiguchi, F., Miyake, N., Kojima, K., Osaka, H., Matsumoto, N., & Okamoto, N. (2021) · Brain and Development · doi:10.1016/j.braindev.2021.07.002 · Cited by 8
Self-citationIs Generalized and Segmental Dystonia Accompanied by Impairments in the Dopaminergic System?
Ikezawa, J., Yokochi, F., Okiyama, R., Kumada, S., Tojima, M., Kamiyama, T., Hanakawa, T., Matsuda, H., Tanaka, F., Nakata, Y., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.751434 · Cited by 8
“In AADC deficiency, dopamine agonist therapy provided the patients with few benefits, but, after AADC gene transfer, the patients showed marked improvement in their dystonia symptoms (43).”
BackgroundGlobal brain delivery of neuroligin 2 gene ameliorates seizures in a mouse model of epilepsy
Oguro, K., Shimazaki, K., Yokota, H., Onuki, Y., Murashima, Y. L., Kawai, K., & Muramatsu, S. (2021) · The Journal of Gene Medicine · doi:10.1002/jgm.3402 · Cited by 8
“need to confirm the long-term effectiveness of induced AAV-NL2 in the future; however, from our experience, a yearly availability of the therapy may be expected.(39,40,42) Although future studies are neces-”
BackgroundSelf-citationCursio, I., Siliquini, S., Carducci, C., Bisello, G., Mastrangelo, M., Leuzzi, V., Bertoldi, M., & Marini, C. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1284339 · Cited by 7
Patient selection considerations for AADC deficiency gene therapy
Roubertie, A., Anselm, I. A., Ben‐Zeev, B., Hwu, W., Kumar, A., Monteleone, B., Muramatsu, S., Leuzzi, V., Ibáñez‐Micó, S., Stone, S. S. D., et al. (2024) · Annals of the Child Neurology Society · doi:10.1002/cns3.20052 · Cited by 7
“12,13,15,22 Gene therapy has also been shown to improve survival in patients with AADC de fi ciency 26 and improve the quality of life of their caregivers.”
BackgroundMethodResultInfluentialSelf-citationGenetic therapies for movement disorders - current status
Sartorelli, J., Ng, J., Rahim, A. A., Waddington, S. N., & Kurian, M. A. (2025) · Journal of Neurology · doi:10.1007/s00415-025-12940-5 · Cited by 8
“Other frequently reported adverse events included pyrexia which was also transient [63, 64].”
Egawa, N., Suzuki, H., Takahashi, R., Hayakawa, K., Li, W., Lo, E. H., Arai, K., & Inoue, H. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20910324 · Cited by 9
“Adeno-associated virus vector has been reported to be relatively safe and applicable to gene therapy for CNS diseases.(111) Intravenous delivery of miRNA/mRNA enwrapped by exosome via leaky BBB reprogramming would be another attractive approach aimed at remodeling the micro-circulating system including pericyte assemb…”
BackgroundOpladen, T., Brennenstuhl, H., Hübschmann, O. K., Call, D., Green, K., Schara, U., Rascher, W., Hövel, A., Assmann, B. E., Kölker, S., et al. (2021) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-021-01232-7 · Cited by 7
“führten mit der gleichen operativen Prozedur und dem gleichen Vektor in Japan eine offene Phase-I/II-Studie mit 6 Patienten (Altersmedian 11 Jahre, Range 4–19) durch [13].”
Williams, K., Skrobanski, H., Buesch, K., & Acaster, S. (2022) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-022-02274-0 · Cited by 9
Buesch, K., Zhang, R., Szczepańska, K., Veličković, V. M., Turner, L., Despotović, M., Đorđević, B., & Russell, A. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2072090 · Cited by 7
“Category Signs and symptoms (number of patients reported with signs/symptoms) Motor function Gross motor delay – No motor function (52), Partial head control (19), Full head control (107), Sitting assisted (3), Sitting unassisted (44), Standing unassisted (43), Walking assisted (1), Walking unassisted (34), Grasp obje…”
BackgroundClinical gene therapy development for the central nervous system: Candidates and challenges for AAVs
Leong, T. W., Pal, A., Cai, Q., Gao, Z., Li, X., Bleris, L. G., Hayenga, H. N., & Qin, Z. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.04.009 · Cited by 8
Smith, A. B., Hanbury, A., de Zárate, I. B. O., Hammès, F., de Pouvourville, G., & Buesch, K. (2021) · Patient Related Outcome Measures · doi:10.2147/prom.s306228 · Cited by 7
Smith, A. B., Hanbury, A., & Buesch, K. (2021) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-021-00403-0 · Cited by 7
“Patients with the severe phenotype will be bedridden for life [2], will not achieve developmental milestones and will be fully dependent for care.”
BackgroundInfluentialLi, X., Wu, Z., Fan, J.-Y., Liu, M., Song, C., Chen, H., Yin, Y., Li, A., Wang, Y., Gao, S., et al. (2024) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2024.05.012 · Cited by 6
Fifteen-minute consultation: Approach to investigation and management of childhood dystonia
Forman, E., King, M. D., & Gorman, K. M. (2020) · Archives of Disease in Childhood Education & Practice · doi:10.1136/archdischild-2019-318131 · Cited by 6
Precision medicine for genetic childhood movement disorders
Soo, A. K. S., Ferrini, A., & Kurian, M. A. (2021) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.14869 · Cited by 7
Muramatsu, S., Hwu, W., & Gidoni-Ben-Zeev, B. (2021) · Current Gene Therapy · doi:10.2174/1566523221666210922155413 · Cited by 6
Self-citationCarlo, E. D., Santagata, S., Sauro, L., Tolve, M., Manti, F., Leuzzi, V., Angeloni, A., & Carducci, C. (2021) · Journal of Chromatography B · doi:10.1016/j.jchromb.2021.122999 · Cited by 6
Obata, Y., Abe, K., Miyazaki, M., Koji, T., Tabata, Y., & Nishino, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24086951 · Cited by 6
“Recently, the progress of gene therapy has been remarkable, and clinical application has begun for hereditary diseases [16–20], malignant tumors [21,22], neurodegenerative diseases [23,24], and cardiovascular diseases [25,26].”
BackgroundSharma, R. K. (2023) · Current Gene Therapy · doi:10.2174/1566523223666230911120922 · Cited by 9
Sternberg, Z. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03684-2 · Cited by 6
“…the results of the clinical outcomes of AAV2-mediated hDDC gene therapy to be more favorable in younger AADC-DT patients compared to older ones [18, 206], suggesting that the relatively shorter duration of the disease in younger subjects may be associated with a less opportunity for the toxic…”
Rizzi, S., Spagnoli, C., Bellini, M., Cesaroni, C. A., Spezia, E., Bergonzini, P., Caramaschi, E., Soliani, L., Turco, E. C., Piccolo, B., et al. (2023) · Genes · doi:10.3390/genes14091828 · Cited by 5
“Gene therapy, in addition to alleviating the disease-related signs and symptoms, leads to improved motor and cognitive performances and is generally well-tolerated [11].”
BackgroundMetabolic Disorders With Associated Movement Abnormalities
Singer, H. S., Mink, J. W., Gilbert, D. L., & Jankovic, J. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-820552-5.00018-8 · Cited by 6
Marchese, F., Faedo, E., Vari, M. S., Bergonzini, P., Iacomino, M., Guerra, A., Franceschetti, L., Baroni, A., Scudieri, P., Minetti, C., et al. (2021) · Journal of Pediatric Epilepsy · doi:10.1055/s-0041-1723768 · Cited by 5
Editorial: Developmental delay and intellectual disability
Banerjee, S., Munshi, A., Li, C., & Ayub, M. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.934815 · Cited by 5
“In the future, more refined cellular andmolecular studies are required to understand the disease mechanisms (Bowling et al., 2017; Karin et al., 2019; Manickam et al., 2021).”
BackgroundAssessment of Immune Responses Against AAV Encoded Transgene Products
Gorovits, B., Azadeh, M., Fiscella, M., Harrison, T., Hofer, M., Janetzki, S., Jawa, V., Long, B. R., Lu, Y., Mahnke, Y. D., et al. (2026) · The AAPS Journal · doi:10.1208/s12248-025-01192-w · Cited by 5
“…cellular immunity, including anti-vector and anti-transgene protein responses, following direct intra-CNS administration (e.g., intraputaminal delivery), have been reported (98, 99) Immunosuppressive treatment regimens have been applied to mitigate potential impact of anti-TP immune response (100).”
Evola, V., & Parmar, M. S. (2026) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2026.2647033 · Cited by 4
Congenital cerebral palsy: genetic cause and nosological integrity
Sokolov, P. M., Chebanenko, N. V., Петрович, З. В., Kanivets, I. V., Георгиевич, П. А., & Romanov, P. A. (2021) · Russian Journal of Child Neurology · doi:10.17650/2073-8803-2020-15-3-4-65-77 · Cited by 4
Harahap, R. S., Noor, R. R., Endrawati, Y. C., Darusman, H. S., & Gunawan, A. (2022) · Animal Bioscience · doi:10.5713/ab.22.0227 · Cited by 4
“Individuals with a DDC gene deficiency will experience decreased serotonin levels which can cause developmental delays and movement disorders [11].”
BackgroundToward Engineered Biosynthesis of Drugs in Human Cells
Matsuda, S., Tsunematsu, Y., Matsushita, T., Ogata, Y., Hachiya, S., Kishimoto, S., Miyoshi, N., & Watanabe, K. (2021) · ChemBioChem · doi:10.1002/cbic.202100645 · Cited by 4
Wang, H., Li, J., Zhou, J., Dai, L., Ding, C., Li, M., Feng, W., Fang, F., Ren, X., & Wang, X. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.919583 · Cited by 4
“Previous research has shown that gene therapy can improve the motor function of individuals with AADC deficiency, and may also improve physiological and cognitive functioning (27, 28).”
BackgroundGene therapy for neurodegenerative disorders in children: dreams and realities
Boespflug‐Tanguy, O., Sevin, C., & Piguet, F. (2023) · Archives de Pédiatrie · doi:10.1016/s0929-693x(23)00225-7 · Cited by 5
Thys, L., Meuwissen, M. E. C., Janssens, K., & Beysen, D. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23746 · Cited by 4
Nardecchia, F., Ricciardi, G., Carducci, C., Mastrangelo, M., Manti, F., Pisani, F., & Leuzzi, V. (2025) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2025.107886 · Cited by 3
Genetic therapies for neurological diseases
Rahim, A. A., Kurian, M. A., Zhou, H., Ferguson, R., Tabrizi, S. J., Lignani, G., Aquilina, K., & Waddington, S. N. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100093 · Cited by 5
“98 AADCd is a rare inherited primary neurotransmitter disorder resulting from biallelic variants in DDC , encoding the final enzyme that catalyzes the conversion of 5-hydroxytryptophan to serotonin and L-dopa to dopamine.”
Smith, A. B., Hanbury, A., Whitty, J. A., & Buesch, K. (2021) · Patient Related Outcome Measures · doi:10.2147/prom.s294628 · Cited by 3
“Introduction Aromatic L-amino decarboxylase (AADC) deficiency is a rare, genetic condition typically presenting in infancy or early childhood with only around 150 reported cases worldwide.(1) Common symptoms including hypotonia, developmental delay, movement disorders, and oculogyric crises.”
BackgroundSmith, A. B., Hanbury, A., Whitty, J. A., de Zárate, I. B. O., Hammes, F., de Pouvourville, G., & Buesch, K. (2022) · Patient Related Outcome Measures · doi:10.2147/prom.s332519 · Cited by 3
“Aromatic L-amino acid decarboxylase (AADC) deficiency is a rare, genetic condition typically presenting in infancy or early childhood with only around 150 reported cases worldwide.(1) Common symptoms include hypotonia, developmental delay, movement disorders, and oculogyric crises.”
Metadata
- Authors
- Kojima, K., Nakajima, T., Taga, N., Miyauchi, A., Kato, M., Matsumoto, A., Ikeda, T., Nakamura, K., Kubota, T., Mizukami, H., Ono, S., Onuki, Y., Sato, T., Osaka, H., Muramatsu, S.-I., & Yamagata, T.
- Affiliations
- Jichi Medical University (JP)
- Yamagata University (JP)
- Anjo Kosei Hospital (JP)
- Utsunomiya Central Clinic, Utsunomiya, Tochigi, Japan
- Corresponding author
- Yamagata, Takanori
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-01-23
- Volume
- 142
- Issue
- 2
- Pages
- 322-333
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC6377184
- OpenAlex
- W2912202854
- Cited by
- 139
- References
- 54
- Citations by year
- 2026: 10 · 2025: 11 · 2024: 14 · 2023: 23 · 2022: 23 · 2021: 34 · 2020: 18 · 2019: 6
- FWCI
- 8.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Agency for Medical Research and Development
- AMED (JP17ek0109168)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- aromatic L-amino acid decarboxylase deficiency, gene therapy, adeno-associated virus vectors, motor function, cognitive function, dystonia, oculogyric crisis, dopamine synthesis, putamen, developmental delay, movement disorders
- MeSH terms
- Adolescent, Amino Acid Metabolism, Inborn Errors, Aromatic-L-Amino-Acid Decarboxylases, Brain, Child, Child, Preschool, Female, Humans, Male, Mental Processes, Motor Skills, Genetic Therapy, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.